Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 301–400 of 1,000
Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson's Disease?
Kanaan, N. M., & Manfredsson, F. P. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-012138 · Cited by 110
“Moreover, aging-related increases in -syn were exaggerated in neuromelanincontaining neurons of the substantia nigra [30], which are more susceptible to degeneration in PD and nonhuman models of PD [31, 32].”
BackgroundHarrington, K. A., Augood, S. J., Kingsbury, A. E., Föster, O., & Emson, P. C. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00278-z · Cited by 98
Rousselet, E., Joubert, C., Callebert, J., Parain, K., Tremblay, L., Orieux, G., Launay, J.-M., Cohen-Salmon, C., & Hirsch, E. C. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00108-6 · Cited by 98
“The presence of dysfunctional dopaminergic perikarya in the SN of MPTP intoxicated mice is reminiscent of the status of the SN in humans with PD, where 20% of the nigral neurons also undergo a degenerative process (Hirsch et al., 1988), indicating that our model is valid in terms of neuronal alteration.”
BackgroundImpaired iron homeostasis in Parkinson’s disease
Double, K. L., Gerlach, M., Youdim, M. B. H., & Riederer, P. F. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_3 · Cited by 115
“Subcellular Proteomics” of Neuromelanin Granules Isolated from the Human Brain
Tribl, F., Gerlach, M., Marcus, K., Asan, E., Tatschner, T., Arzberger, T., Meyer, H. E., Bringmann, G., & Riederer, P. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400117-mcp200 · Cited by 98
“A relationship between the loss of the dopaminergic SN cells and their NM content (3), a specific affinity to iron (4), and a significant binding of -synuclein to NM in the diseased state (5) suggest a functional role for NM in neurodegeneration in Parkinson disease (6).”
BackgroundThe Cellular Environment Affects Monomeric α-Synuclein Structure
Stephens, A. D., Zacharopoulou, M., & Kaminski Schierle, G. S. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.005 · Cited by 96
Maruyama, W., Sobue, G., Matsubara, K., et al. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13389-4 · Cited by 97
Muthane, U., Yasha, T. C., & Shankar, S. K. (1998) · Annals of Neurology · doi:10.1002/ana.410430304 · Cited by 97
Bordia, T., Grady, S. R., McIntosh, J. M., & Quik, M. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035998 · Cited by 103
“…dopamine neuron survival (Gerfen et al., 1987a; German et al., 1992; Liang et al., 1996), whereas neuromelanin has been negatively associated (Hirsch et al., 1988; Herrero et al., 1993; Zecca et al., 2003; McCormack et al., 2004), although a definitive relationship of either of these markers…”
BackgroundManning-Bog, A., Caudle, W. M., Perez, X. A., Reaney, S. H., Paletzki, R. F., Isla, M. Z., Chou, V., McCormack, A. L., Miller, G. W., Langston, J. W., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.03.014 · Cited by 104
“Furthermore, the higher risk for oxidative damage conferred by DJ1 deficiency may be particularly relevant to the nigrostriatal system due to the enhanced susceptibility of DAergic neurons to oxidative stress (Heikkila, 1985; Hirsch et al., 1988; Gotz et al., 1990; Hirsch, 1992).”
Dopamine efflux by MPTP and hydroxyl radical generation
Obata, T. (2002) · Journal of Neural Transmission · doi:10.1007/s00702-001-0683-2 · Cited by 103
“Oxidative stress may be involved in the pathogenesis of Parkinson’s disease (Dexter et al., 1989; Riederer et al., 1989; Hirsch et al., 1988; Ben-Shachar et al., 1991).”
BackgroundDopamine, tremor, and Parkinson's disease.
Hirsch, E. C., Mouatt, A., Faucheux, B., Bonnet, A., Graybiel, A., & Agid, Y. (1992) · The Lancet · doi:10.1016/0140-6736(92)90457-e · Cited by 97
Self-citationGonzález‐Hernández, T., Barroso‐Chinea, P., de la Cruz Muros, I., del Mar Pérez‐Delgado, M., & Rodríguez, M. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.20323 · Cited by 96
“…SN; (Dahlström and Fuxe, 1964) are more susceptible than those in A8 (retrorubral field) and A10, which include the ventral tegmental area (VTA), parabrachial pigmented nucleus (PBP), rostral and caudal linear nuclei (Li), and interfascicular nucleus (IF; Hirsch et al., 1988; Goto et al., 1989).”
BackgroundRoussa, E., Wiehle, M., Dünker, N., Becker‐Katins, S., Oehlke, O., & Krieglstein, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0514 · Cited by 96
Glutamate and Mitochondria: Two Prominent Players in the Oxidative Stress-Induced Neurodegeneration
Cassano, T., Pace, L., Bedse, G., Michele Lavecchia, A., De Marco, F., Gaetani, S., & Serviddio, G. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666151218132725 · Cited by 95
Ben‐Shachar, D., Eshel, G., Riederer, P. F., & Youdim, M. B. H. (1992) · Annals of Neurology · doi:10.1002/ana.410320718 · Cited by 101
Pham, C. L. L., Leong, S. L., Ali, F. E. A., Kenche, V. B., Hill, A. F., Gras, S. L., Barnham, K. J., & Cappai, R. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.02.007 · Cited by 103
Parkinson Disease Protein DJ-1 Binds Metals and Protects against Metal-induced Cytotoxicity
Björkblom, B., Adilbayeva, A., Maple-Grødem, J., Piston, D., Ökvist, M., Xu, X. M., Brede, C., Larsen, J. P., & Møller, S. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.482091 · Cited by 95
“Selective degeneration of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and depletion of striatal dopamine levels are the cardinal features of PD (1).”
BackgroundHung, H.-C., & Lee, E. H. Y. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(97)00206-2 · Cited by 98
Waldmeier, P. C., Bozyczko‐Coyne, D., Williams, M. J., & Vaught, J. L. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.031 · Cited by 101
Käufer, C., Schreiber, C. S., Hartke, A.-S., Denden, I., Stanelle‐Bertram, S., Beck, S., Kouassi, N. M., Beythien, G., Becker, K., Schreiner, T., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103999 · Cited by 98
“68,69 The overlap with post-COVID-19 symptoms is notable, and a significant subset of patients with Parkinson (cid:2) s disease presents with worsening of symptoms after remission of COVID-19.”
Reactive Dopamine Metabolites and Neurotoxicity
Hastings, T. G., Lewis, D. A., & Zigmond, M. J. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9480-9_13 · Cited by 111
Functional Genomics of Brain Aging and Alzheimers Disease: Focus on Selective Neuronal Vulnerability
Wang, X., L. Michaelis, M., & K. Michaelis, E. (2010) · Current Genomics · doi:10.2174/138920210793360943 · Cited by 93
“Besides aging and AD, this phenomenon, of selective neuronal vulnerability (SNV), is also a characteristic of many other neural insults, such as Parkinson’s disease [11], amyotrophic lateral sclerosis (ALS) [12], ischemia [13], epileptic seizures [14], and oxidative stress (OS) [15, 16].”
BackgroundPattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism
Snow, B. J. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.3.313 · Cited by 93
Animal models of Parkinson’s disease in rodents induced by toxins: an update
Hirsch, É. C., Höglinger, G. U., Rousselet, E., Breidert, T., Parain, K., Féger, J., Ruberg, M., Prigent, A., Cohen‐Salmon, C., & Launay, J. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0643-3_6 · Cited by 105
Li, Y., Gu, Y., Zheng, B., Luo, L. E., Li, C., Yan, X., Zhang, T., Lu, N., & Zhang, Z. (2016) · Talanta · doi:10.1016/j.talanta.2016.10.016 · Cited by 92
Dopaminergic cell group A8 in the monkey: Anatomical organization and projections to the striatum
François, C., Yelnik, J., Tandé, D., Agid, Y., & Hirsch, E. C. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991122)414:3<334::aid-cne4>3.3.co;2-o · Cited by 92
Self-citationHorellou, P., Marlier, L. N. J. L., Privat, A., et al. (1990) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1990.tb00389.x · Cited by 92
Mangano, E. N., & Hayley, S. P. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.020 · Cited by 100
Meissner, W. G., Prunier, C., Guilloteau, D., Chalon, S., Gross, C. E., & Bézard, E. (2003) · Molecular Neurobiology · doi:10.1385/mn:28:3:209 · Cited by 105
“They identified compartmental subdivisions within the SNc (Damier et al., 1999a), each of them distinctively affected by the progression of the disease (Damier et al., 1999b; Hirsch et al., 1988).”
BackgroundRyvlin, P., Broussolle, E., Piollet, H., Viallet, F., Khalfallah, Y., & Chazot, G. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540300057013 · Cited by 91
Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca 2+
Toulorge, D., Guerreiro, S., Hild, A., Maskos, U., Hirsch, É. C., & Michel, P. P. (2011) · The FASEB Journal · doi:10.1096/fj.11-182824 · Cited by 93
“Alternatively, NIC could simply restore the expression of TH in diseased DA neurons losing their neurotransmitter phenotype (7).”
BackgroundOxidative stress in Parkinson's disease
Schapira, A. H. V. (1995) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1995.tb01022.x · Cited by 90
Offen, D., Ziv, I., Barzilai, A., Gorodin, S., Glater, E., Hochman, A., & Melamed, E. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(96)00150-7 · Cited by 103
The endosomal pathway in Parkinson's disease
Perrett, R. M., Alexopoulou, Z., & Tofaris, G. K. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.009 · Cited by 104
“degeneration (Hirsch et al., 1988) and identified endolysosomalmarkers”
BackgroundElectrochemical dopamine sensor based on superionic conducting potassium ferrite
Sun, X., Zhang, L., Zhang, X., et al. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112045 · Cited by 89
Depboylu, C., Schäfer, M. K.-H., Arias-Carrión, O., Oertel, W. H., Weihe, E., & Höglinger, G. U. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31820805b9 · Cited by 89
“Parkinson disease (PD) is clinically characterized by an akinetic-rigid syndrome caused by a progressive demise of neuromelanin (NM)-containing dopaminergic neurons in the substantia nigra pars compacta (SNc) (19).”
BackgroundDrug treatment of Parkinson’s disease
Drukarch, B., & Muiswinkel, F. L. V. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00340-8 · Cited by 92
Horellou, P., Guibert, B., Leviel, V., & Mallet, J. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7233 · Cited by 95
Prediger, R. D., Aguiar, A. S., MATHEUS, F. C., Walz, R., Antoury, L., Raisman‐Vozari, R., & Doty, R. L. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9281-8 · Cited by 93
Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions
Bender, A., Schwarzkopf, R.-M., McMillan, A., Krishnan, K. J., Rieder, G., Neumann, M., Elstner, M., Turnbull, D. M., & Klopstock, T. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0892-9 · Cited by 94
“Even though we did not employ immunostaining for cell characterization, it can be safely assumed that we studied the dopaminergic class of midbrain neurons, which are at the focus of neurodegeneration in PD [23].”
MethodБолдырев, А. А., Stvolinsky, S. L., Tyulina, O. V., Кошелев, В. Б., Hori, N., & Carpenter, D. O. (1997) · Cellular and Molecular Neurobiology · doi:10.1023/a:1026374114314 · Cited by 87
Zhang, P., Hirsch, É. C., Damier, P., Duyckaerts, C. J., & Javoy-Agid, F. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90004-l · Cited by 89
Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences
Sergi, D., Renaud, J., Simola, N., & Martinoli, M.-G. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00302 · Cited by 86
Zesiewicz, T. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000764 · Cited by 129
Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease
Hirsch, E. C., Graybiel, A. M., & Agid, Y. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb01778.x · Cited by 85
Self-citationYokoyama, H., Kuroiwa, H., Yano, R., & Araki, T. (2008) · Neurological Sciences · doi:10.1007/s10072-008-0986-2 · Cited by 95
“Parkinson’s disease (PD) is a progressive and age-related neurodegenerative disease characterized by degeneration of dopaminergic neurons originating in the substantia nigra pars compacta and projecting to the dorsal striatum [ 1 ].”
Homberg, U., Vitzthum, H., M�ller, M., & Binkle, U. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990705)409:3<495::aid-cne12>3.0.co;2-f · Cited by 80
Mori, F., Nishie, M., Kakita, A., Yoshimoto, M., Takahashi, H., & Wakabayashi, K. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000230520.47768.1a · Cited by 85
Pijak, D. S., Hall, G. F., Tenicki, P. J., Boulos, A. S., Lurie, D. I., & Selzer, M. E. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960513)368:4<569::aid-cne8>3.0.co;2-2 · Cited by 45
Self-citationOssowska, K., Śmiałowska, M., Kuter, K., Wierońska, J., Zięba, B., Wardas, J., Nowak, P., Dąbrowska, J., Bortel, A., Biedka, I., et al. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.039 · Cited by 84
Molecular heterogeneity of midbrain dopaminergic neurons – Moving toward single cell resolution
Anderegg, A., Poulin, J.-F., & Awatramani, R. B. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.022 · Cited by 94
Systemic administration of MPTP induces thalamic neuronal degeneration in mice
Freyaldenhoven, T. E., Ali, S. F., & Schmued, L. C. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00045-0 · Cited by 90
Berg, D., & Riederer, P. F. (2004) · Springer eBooks · doi:10.1007/978-3-642-18741-4_8 · Cited by 84
Schizophrenia: a disease of interhemispheric processes at forebrain and brainstem levels?
Doty, R. W. (1989) · Behavioural Brain Research · doi:10.1016/s0166-4328(89)80087-7 · Cited by 85
Minakaki, G., Krainc, D., & Burbulla, L. F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580634 · Cited by 92
Jung, C.-G., Hida, H., Nakahira, K., Ikenaka, K., Kim, H.-J., & Nishino, H. (2004) · The FASEB Journal · doi:10.1096/fj.03-0927fje · Cited by 82
“Neurons arising from the substantia nigria nd projecting to the striatum are involved in motor control, an d their degeneration is associated with Parkinson’s disease (1).”
BackgroundAhlskog, J. E. (2005) · Movement Disorders · doi:10.1002/mds.20362 · Cited by 83
Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease
Saper, C. B., Sorrentino, D. M., German, D. C., & Lacalle, S. D. (1991) · Annals of Neurology · doi:10.1002/ana.410290602 · Cited by 83
The Oxygen Paradox, the French Paradox, and age-related diseases
Davies, J. M. S., Cillard, J., Friguet, B., Cadenas, E., Cadet, J., Cayce, R., Fishmann, A., Liao, D., Bulteau, A.-L., Derbré, F., et al. (2017) · GeroScience · doi:10.1007/s11357-017-0002-y · Cited by 82
“Several lines of evidence suggest oxidative stress plays a very special role in the degeneration of melanized dopamine in Parkinson disease, which are particularly sensitive to oxygen radicals (Hirsch et al. 1988).”
BackgroundWengler, K., He, X., Abi‐Dargham, A., & Horga, G. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116457 · Cited by 89
“This is consistent with reports of higher degree of NM pigmentation in the SN than the VTA (Hirsch et al., 1988; Liang et al., 2004).”
Parkinson's disease: From bench to bedside
Draoui, A., Hiba, O. E., Aimrane, A., Khiat, A. E., & Gamrani, H. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2019.11.002 · Cited by 92
Karlsson, O., Berg, C., Brittebo, E. B., & Lindquist, N. G. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00508.x · Cited by 82
“In PD, there is a selective loss of dopaminergic neurons containing neuromelanin, whereas the non-pigmented dopaminergic neurons are spared (Hirsch et al., 1988; Kastner et al., 1992).”
BackgroundInfluentialMorel, P., Tallineau, C., Pontcharraud, R., Piriou, A., & Huguet, F. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(98)00062-x · Cited by 95
Crocker, S. J., Wigle, N., Liston, P., Thompson, C. S., Lee, C. J., Xu, D., Roy, S., Nicholson, D. W., Park, D. S., MacKenzie, A., et al. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01653.x · Cited by 85
“Parkinsonism is principally attributed to the selective loss of the pigmented dopaminergic neurons of the substantia nigra pars compacta (SNc), located in the ventral midbrain (Hirsch et al., 1988).”
BackgroundStriatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells
Barroso‐Chinea, P., Cruz‐Muros, I., Aymerich, M. S., Rodríguez, M., Afonso‐Oramas, D., Lanciego, J. L., & González‐Hernández, T. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04024.x · Cited by 91
“…et al., 1996; Gonzalez-Hernandez & Rodriguez, 2000) and the topographical pattern of degeneration observed in PD (Bernheimer et al., 1973; Hirsch et al., 1988; Damier et al., 1999) and different models of PD (Chiueh et al., 1985; Schneider et al., 1987; Herrero et al., 1993; Varastet et…”
Laar, A. D. V., Webb, K. R., Keeney, M. T., Laar, V. S. V., Zharikov, A., Burton, E. A., Hastings, T. G., Glajch, K. E., Hirst, W. D., Greenamyre, J. T., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00561-6 · Cited by 95
Hegedus, Z. L. (2000) · Toxicology · doi:10.1016/s0300-483x(00)00157-8 · Cited by 90
Santiago, R. M., Barbiero, J. K., Gradowski, R. W., Boschen, S. L., Lima, M. M. S., Cunha, C. D., Andreatini, R., & Vital, M. A. B. F. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.10.035 · Cited by 87
Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites
Hastings, T. G., & Zigmond, M. J. (1997) · Springer eBooks · doi:10.1007/978-3-7091-6844-8_11 · Cited by 81
Hurd, Y. L., Pristupa, Z. B., Herman, M. M., Niznik, H. B., & Kleinman, J. E. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90535-5 · Cited by 90
Frequency-dependent neural activity in Parkinson's disease
Hou, Y., Wu, X., Hallett, M., Chan, P., & Wu, T. (2014) · Human Brain Mapping · doi:10.1002/hbm.22587 · Cited by 80
“Degeneration of the dopamine neurons in the substantia nigra is the most prominent; in contrast, dopamine neurons in the ventral tegmental area are much less affected [Braak et al., 2004; Damier et al., 1999; Hirsch et al., 1988].”
BackgroundThe Peptidyl-prolyl Isomerase Pin1 Up-regulation and Proapoptotic Function in Dopaminergic Neurons
Ghosh, A., Saminathan, H., Kanthasamy, A., Anantharam, V., Jin, H., Sondarva, G. V., Harischandra, D. S., Qian, Z., Rana, A., & Kanthasamy, A. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444224 · Cited by 88
“Human midbrain contains both pigmented (with neuromelanin) and non-pigmented (without neuromelanin) dopaminergic neurons (37), and in the diseased condition, the neuromelanin-containing pigmented dopaminergic neurons degenerate more than the non-pigmented (38).”
BackgroundBiochemistry of Parkinson's disease with special reference to the dopaminergic systems
Hirsch, É. C. (1994) · Molecular Neurobiology · doi:10.1007/bf02816113 · Cited by 90
Calcium, Bioenergetics, and Parkinson’s Disease
Zampese, E., & Surmeier, D. J. (2020) · Cells · doi:10.3390/cells9092045 · Cited by 79
Dopamine neuron ensembles signal the content of sensory prediction errors
Stalnaker, T. A., Howard, J. D., Takahashi, Y. K., Gershman, S. J., Kahnt, T., & Schoenbaum, G. (2019) · eLife · doi:10.7554/elife.49315 · Cited by 74
“In humans, the total number is about 300,000 (Hirsch et al., 1988).”
Post, M. R., Lieberman, O. J., & Mosharov, E. V. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00161 · Cited by 85
“Specifically, SNpc and LC catecholaminergic neurons degenerate in PD, whereas ventral tegmental area (VTA) and tuberoinfundibular DA neurons are relatively spared in both PD patients and laboratory models of the disorder (Hirsch et al., 1988; Braak et al., 1995).”
BackgroundHuman Paraoxonase-2 (PON2): Protein Functions and Modulation
Manco, G., Porzio, E., & Carusone, T. M. (2021) · Antioxidants · doi:10.3390/antiox10020256 · Cited by 81
Oxidative stress and Parkinson's disease
Jenner, P. G. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83024-7 · Cited by 89
Loss of C1 and C3 epinephrine‐synthesizing neurons in the medulla oblongata in parkinson's disease
Gai, W., Geffen, L. B., Denoroy, L., & Blessing, W. W. (1993) · Annals of Neurology · doi:10.1002/ana.410330405 · Cited by 83
Parkinson's disease: Insights from non-traditional model organisms
Pienaar, I. S., Götz, J., & Feany, M. Β. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.001 · Cited by 84
Kurosaki, R., Muramatsu, Y., Kato, H., & Araki, T. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.03.006 · Cited by 80
Vulnerability of the Hippocampus to Insults: Links to Blood–Brain Barrier Dysfunction
Davidson, T. L., & Stevenson, R. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041991 · Cited by 90
“PD is characterized by its clinical motor symptoms resulting from damage to the nigrostriatal pathway [246].”
BackgroundRodríguez, M., Abdala, P., Barroso‐Chinea, P., Obeso, J. A., & González‐Hernández, T. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00168-1 · Cited by 89
Studies on genomic DNA topology and stability in brain regions of Parkinson’s disease
Hegde, M. L., Gupta, V. B., Anitha, M., Harikrishna, T., Shankar, S. K., Muthane, U., Subba Rao, K., & Jagannatha Rao, K. S. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.02.018 · Cited by 77
Wisman, L. A. B., Sahin, G., Maingay, M., Leanza, G., & Kirik, D. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1885-08.2008 · Cited by 77
“Parkinson’s disease (PD) is clinically characterized by motor dysfunction, and it is defined pathologically by a prominent loss of dopamine (DA)-synthesizing neurons in the substantia nigra (SN) (Hirsch et al., 1988; Fearnley and Lees, 1991).”
Quik, M., Chen, L., Parameswaran, N., Xie, X., Langston, J. W., & McCallum, S. E. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0215-06.2006 · Cited by 77
“These gradients are associated with distinct patterns of striatal degeneration with nigrostriatal damage, with more severe dopaminergic losses in dorsolateral compared with ventromedial regions and greater declines in the putamen than caudate in animal models and Parkinson’s disease (Parent et al., 1983; Hirsch et al.…”
BackgroundCompartmentalization of excitatory amino acid receptors in human striatum.
Dure, L. S., Young, A. B., & Penney, J. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7688 · Cited by 79
Chiu, W., Depboylu, C., Hermanns, G., Maurer, L., Windolph, A., Oertel, W. H., Ries, V., & Höglinger, G. U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.020 · Cited by 84
Depierreux, F., Parmentier, E., Mackels, L., Baquero, K., Degueldre, C., Balteau, E., Salmon, E., Phillips, C., Bahri, M. A., Maquet, P., et al. (2021) · npj Parkinson's Disease · doi:10.1038/s41531-021-00199-2 · Cited by 75
Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?
Damier, P., Kästner, A., Agid, Y., & Hirsch, É. C. (1996) · Neurology · doi:10.1212/wnl.46.5.1262 · Cited by 76
Self-citationHorowitz, M. P., Milanese, C., Di Maio, R., Hu, X., Montero, L. M., Sanders, L. H., Tapias, V., Sepe, S., van Cappellen, W. A., Burton, E. A., et al. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3629 · Cited by 75
“In the pathogenesis of PD, DA neurons in the SNpc degenerate more severely than DA neurons in the adjacent VTA, which are relatively spared (19, 30, 58).”
BackgroundHaavik, J., Almås, B., & Flatmark, T. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010328.x · Cited by 76
“…particular iron) and neuromelanin (or a compound related to this substance) in the substantia nigra has also been proposed to contribute to the nonenzymatic generation of H202 and conversion of this compound to the highly reactive hydroxyl (0H) radical (Hirsch et al., 1988; Fahn and Cohen, 1992).”
BackgroundDemethoxycurcumin: A naturally occurring curcumin analogue for treating non‐cancerous diseases
Hatamipour, M., Ramezani, M., Tabassi, S. A. S., Johnston, T. P., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28626 · Cited by 85
Gjedde, A., Léger, G. C., Cumming, P., Yasuhara, Y., Evans, A. C., Guttman, M., & Kuwabara, H. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13651.x · Cited by 75
The pathology roadmap in Parkinson disease
Surmeier, D. J., & Sulzer, D. (2013) · Prion · doi:10.4161/pri.23582 · Cited by 74
“Some Lewy pathology has been reported in the neighboring ventral tegmental area and retrorubral field neurons as well,(53) but neuronal loss in these two regions is variable.(36,37) Profound neuronal loss in the SNc appears to be specific to parkinsonian etiologies(119) and not Alzheimer disease.”
BackgroundRamkumar, M., Rajasankar, S., Gobi, V. V., Dhanalakshmi, C., Manivasagam, T., Thenmozhi, A. J., Essa, M. M., Kalandar, A., & Chidambaram, R. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1720-5 · Cited by 117
“Background Parkinson’s disease (PD) is one of the most common and progressive neurodegenerative disease, which affects the movement of aged population and is characterized by the selective loss of dopaminergic neurons in the substantia nigra of pars compacta (SNpc) [1] and depletion of dopamine (DA), a neurotransmitte…”
BackgroundFu, X., Wang, Y., He, X., Li, H., Liu, H., & Zhang, X. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01284-w · Cited by 74
Gerlach, M., Maetzler, W., Broich, K., Hampel, H. J., Rems, L., Reum, T., Riederer, P. F., Stöffler, A., Streffer, J. R., & Berg, D. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0682-x · Cited by 80
“…PET positron emission tomography, SPECT single photon emission computed tomography PD is neuropathologically characterised at the cellular level by a relative selective destruction of neuromelanin (NM)-containing dopaminergic cells in the SN pars compacta (Hirsch et al. 1988).”
BackgroundKästner, A., Hirsch, É. C., Agid, Y., & Javoy-Agid, F. (1993) · Brain Research · doi:10.1016/0006-8993(93)91005-d · Cited by 74
Self-citation
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.